ABOS:NASDAQ, Acumen Pharmaceuticals, Inc.

Why ABOS stock fell on November 18

Acumen Pharmaceuticals, Inc. fell 15.7% on Wednesday, November 18, 2026, on 3,082,100 shares. No headline about ABOS came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

ABOS stock overview

Acumen Pharmaceuticals, Inc. (ABOS:NASDAQ) closed at $0.187 on November 20, 2026, down 3.52% on the day. The stock trades 94.8% below its 52-week high of $3.60 and 16.5% above its 52-week low of $0.160. Over the past year, it lost 89.0%. Acumen Pharmaceuticals, Inc. is part of the Health Care sector.

Key figures

Price
$0.187
Day change
-3.52%
Volume
2,712,979
Average volume
2,696,160
Market cap
13M+
52-week range
$0.160 – $3.60
50-day average
$1.62
200-day average
$2.36

Price action over the past year

In 251 trading sessions since November 20, 2025, ABOS closed higher on 122 days (49%). Its best day was January 27, 2026 (+30.77%) and its worst was November 18, 2026 (-15.65%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

ABOS news

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Similar stocks

Find more stocks like ABOS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.